Sanofi (SNYNF) Cash from Restructuring (2009 - 2016)
Sanofi's (SNYNF) quarterly Cash from Restructuring came in at -$551.5 million in Q1 2016, down 38.28% year-on-year from -$893.6 million in Q2 2015, and down 40.15% quarter-over-quarter from -$393.5 million in Q4 2015.
Sanofi (SNYNF) Cash from Restructuring (2009 - 2016) Analysis & Trends
Sanofi has disclosed Cash from Restructuring across 8 years of filings, most recently posting -$551.5 million for Q1 2016.
- Cash from Restructuring for Q1 2016 came in at -$551.5 million, down 38.28% year-over-year; the trailing twelve-month figure through Mar 2016 was -$1.0 billion (down 411.34% YoY), and the FY2015 annual result was -$398.8 million, down 172.99% from the prior year.
- Cash from Restructuring came in at -$551.5 million for Q1 2016 at Sanofi, down from -$393.5 million in the prior quarter.
- In the past five years, Cash from Restructuring ranged from a high of $1.5 billion in Q4 2012 to a low of -$551.5 million in Q1 2016.
- The 5-year median for Cash from Restructuring is $69.9 million (2014), against an average of $49.3 million.
- Across the five-year window, Cash from Restructuring surged 241.31% in 2012 and sank 670.67% in 2015, its largest moves.
- Sanofi's Cash from Restructuring stood at $1.5 billion in 2012, then slumped by 72.41% to $408.3 million in 2013, then tumbled by 133.36% to -$136.2 million in 2014, then plunged by 188.85% to -$393.5 million in 2015, then sank by 40.15% to -$551.5 million in 2016.
- The last three Cash from Restructuring figures came in at -$551.5 million (Q1 2016), -$393.5 million (Q4 2015), and -$64.5 million (Q3 2015), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn |
| 10 | Sanofi | - | - | 9.49 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2016 | -551.51 Mn |
| Dec 31, 2015 | -393.51 Mn |
| Sep 30, 2015 | -64.51 Mn |
| Jun 30, 2015 | -30.94 Mn |
| Mar 31, 2015 | -398.83 Mn |
| Dec 31, 2014 | -136.23 Mn |
| Sep 30, 2014 | 216.35 Mn |
| Jun 30, 2014 | 115.24 Mn |
| Mar 31, 2014 | 69.89 Mn |
| Dec 31, 2013 | 408.33 Mn |
| Sep 30, 2013 | 94.08 Mn |
| Jun 30, 2013 | -207.61 Mn |
| Mar 31, 2013 | 71.30 Mn |
| Dec 31, 2012 | 1.48 Bn |
| Sep 30, 2012 | 71.28 Mn |
| Jun 30, 2012 | 209.45 Mn |
| Mar 31, 2012 | -114.08 Mn |
| Dec 31, 2011 | -1.05 Bn |
| Sep 30, 2011 | -99.02 Mn |
| Jun 30, 2011 | -496.28 Mn |